UnitedHealth Group 8-K
PositiveEarningsGuidance raised
Pricing discipline lowered the medical care ratio as UnitedHealthcare and Optum strengthened; FY2026 earnings guidance rose.
Filed 2026-07-16 06:00 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Q2 2026 results with raised FY2026 guidance. Revenue was nearly flat Y/Y, while earnings from operations increased on stronger performance across UnitedHealthcare and Optum. A lower medical care ratio reflected pricing discipline, benefit design and medical cost management; the quarter also included $860M of net favorable prior-period medical reserve development.
Key Figures
| Metric | Q2 2026 | Q2 2025 | Y/Y |
|---|---|---|---|
| Revenue | $112.0B | $111.6B | +0.4% |
| Earnings from operations | $7.99B | $5.15B | +55% |
| Net earnings attributable to UnitedHealth Group common shareholders | $5.48B | $3.41B | +61% |
| Diluted EPS | $6.04 | $3.74 | +61% |
| Adjusted diluted EPS, non-GAAP | $6.38 | $4.08 | +56% |
- Medical care ratio: 86.7%, down 270 bp Y/Y; operating cost ratio: 12.7%, up 40 bp, reflecting targeted investments in technology, operations and community support.
- Cash flows from operations were $11.1B, or 1.9× net income, reflecting a substantial government payment, strong earnings and disciplined working capital management. The debt-to-capital ratio was 41.2% at 6/30/2026, vs 44.1% a year earlier.
- Repurchased $4.0B of shares through mid-July and reported diluted weighted-average shares of 906M, down from 910M Y/Y. UnitedHealthcare served 48.5M people, down 525,000 sequentially; Optum Rx adjusted scripts were 387M, vs 414M Y/Y.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Reported operating earnings, UnitedHealthcare | FY2026 | >$12B | >$10.8B | Raised |
| Reported operating earnings, Optum Health | FY2026 | >$2.275B | >$2.2B | Raised |
| Reported operating earnings, Optum Insight | FY2026 | >$4.925B | >$4.75B | Raised |
| Reported operating earnings, Optum Rx | FY2026 | >$6.25B | >$6.25B | Reaffirmed |
| Reported operating earnings, Optum | FY2026 | >$13.45B | >$13.2B | Raised |
| Reported operating earnings, UnitedHealth Group | FY2026 | >$25.45B | >$24B | Raised |
| Adjusted operating earnings, Optum Health, non-GAAP | FY2026 | >$2.215B | >$1.577B | Raised |
| Adjusted operating earnings, Optum Insight, non-GAAP | FY2026 | >$4.75B | >$4.75B | Reaffirmed |
| Adjusted operating earnings, Optum Rx, non-GAAP | FY2026 | >$6.25B | >$6.25B | Reaffirmed |
| Adjusted operating earnings, Optum, non-GAAP | FY2026 | >$13.215B | >$12.577B | Raised |
| Adjusted operating earnings, UnitedHealth Group, non-GAAP | FY2026 | >$25.215B | — | — |
| Net earnings attributable to UnitedHealth Group shareholders, GAAP | FY2026 | >$16.75B | >$15.6B | Raised |
| Diluted EPS attributable to UnitedHealth Group shareholders, GAAP | FY2026 | $18.45-$18.95 | >$17.10 | Raised |
| Adjusted diluted EPS, non-GAAP | FY2026 | $19.50-$20.00 | >$17.75 | Raised |
| Medical care ratio | FY2026 | 88.1% ± 25 bp | 88.8% ± 50 bp | Lowered |
| Tax rate | FY2026 | ≈18.5% | ≈19.25% | Lowered |
| Cash flows from operations | FY2026 | ≈$24B | >$18B | Raised |
| Share repurchases | FY2026 | At least $5B | ≈$2.5B | Raised |
Investor Takeaways
- Track medical care costs and membership trends against the FY2026 outlook, particularly after the quarter’s favorable reserve development and sequential decline in UnitedHealthcare membership.
- Watch execution against the increased annual earnings and cash flow outlook, including the planned share repurchases.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3